

Six-Year Zoledronic Acid Regimen Safe, Effective


BY MITCHEL L. ZOLER

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH

TORONTO – Patients who continued annual treatment with zoledronic acid for 6 years had significantly better bone mineral density and fewer morphometric vertebral fractures than did patients who received 3 years of treatment and then stopped, according to results of a controlled study with more than 1,200 subjects.

Six continuous years of annual zoledronic acid treatment also proved safe, making continued treatment with this bisphosphonate formulation an option for patients who might benefit, Dennis M. Black, Ph.D., said at the meeting.

“After 3 years, it might be beneficial for some women, particularly those at high



The decision to continue bisphosphonate treatment long term must be individualized.

DR. BLACK

vertebral fracture risk, to continue zoledronic acid for an additional 3 years,” said Dr. Black, professor of epidemiology and biostatistics at the University of California, San Francisco.

“These new findings show that continued treatment with zoledronic acid for 6 years continues to maintain bone mass and reduced vertebral fracture risk with no change to its favorable safety profile compared with discontinuation of treatment after 3 years,” he said in a written statement.

On the other hand, the decision to continue bisphosphonate treatment long term must be individualized, he said.

It may be possible to identify women who would benefit from a drug holiday, he added.

In light of the new finding, zoledronic acid joins other bisphosphonates, such as alendronate, shown to prevent loss of bone density when the drug is continued after several years of treatment.

In a previous report, continuing treatment with alendronate for 5 years following an initial 5 years of treatment led to less bone density loss than in patients who switched from alendronate to placebo (JAMA 2006;296:2927-38).

The same alendronate study failed to show that continued bisphosphonate treatment led to a reduced rate of morphometric vertebral fractures, compared with stopping alendronate.

The new zoledronic acid findings came from an extension of the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial, which compared a single, annual infusion of zoledronic acid with placebo in post-

menopausal women with osteoporosis during 3 years of treatment (N. Engl. J. Med. 2007;356:1809-22).

Dr. Black and his associates randomized 1,233 women who completed the zoledronic acid arm of the study to either continue with another 3 years of annual infusions of 5 mg zoledronic acid or switch to placebo.

The average age of the study subjects was 76 years, and approximately 55%

had a femoral neck T score of less than –2.5.

At the conclusion of the study, the percent change in femoral neck bone mineral density, compared with the level at entry into the study, averaged 1% higher in patients who were treated with zoledronic acid, a statistically significant difference in the study’s primary end point.

Femoral neck bone mineral density in

the zoledronic acid–treated patients increased by an average of 1.4% over baseline 6 years earlier (when they started on the drug), compared with those who switched off the bisphosphonate after 3 years, a statistically significant difference.

The rate of morphometric vertebral fractures during the 3 years of the new study totaled 6% in the patients who were on placebo and 3% in those who

For adult patients with type 2 diabetes in addition to diet and exercise

Add Onglyza™ to improve glycemic control

- Onglyza significantly improved glycemic control across A1C, FPG, and PPG when added to metformin, glyburide, or a TZD*
- In a pooled analysis of add-on and monotherapy trials the overall incidence of adverse events was similar to placebo (72% vs 71%, respectively)
 - Discontinuation of therapy due to adverse events occurred in 3.3% and 1.8% of patients receiving Onglyza and placebo, respectively
- Onglyza is widely accessible,¹ with most commercially-insured eligible patients paying only \$10 per month†

Indication and Important Limitations of Use

ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

ONGLYZA has not been studied in combination with insulin.

Important Safety Information

- **Use with Medications Known to Cause Hypoglycemia:** Insulin secretagogues, such as sulfonylureas, cause hypoglycemia. Therefore, a lower dose of the insulin secretagogue may be required to reduce the risk of hypoglycemia when used in combination with ONGLYZA
- **Macrovascular Outcomes:** There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ONGLYZA or any other antidiabetic drug
- **Most common adverse reactions** (regardless of investigator assessment of causality) reported in ≥5% of patients treated with ONGLYZA and more commonly than in patients treated with control were upper respiratory tract infection (7.7%, 7.6%), headache (7.5%, 5.2%), nasopharyngitis (6.9%, 4.0%) and urinary tract infection (6.8%, 6.1%)
- When used as add-on combination therapy with a thiazolidinedione, the incidence of peripheral edema for ONGLYZA 2.5 mg, 5 mg, and placebo was 3.1%, 8.1% and 4.3%, respectively

Laboratory Tests: There was a dose-related mean decrease in absolute lymphocyte count observed with ONGLYZA.

Drug Interactions: Because ketoconazole, a strong CYP3A4/5 inhibitor, increased saxagliptin exposure, the dose of ONGLYZA should be limited to 2.5 mg when coadministered with a strong CYP3A4/5 inhibitor (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin).

were on zoledronic acid, a statistically significant difference.

The two treatment arms showed no significant difference in their rates of nonvertebral fractures. Continued zoledronic acid treatment also led to reduced blood levels of a marker of bone turnover compared with the patients who received placebo injections.

Six years of annual zoledronic acid treatment appeared safe, with no excess of adverse events or serious adverse events compared with the patients on 3 years of placebo. The researchers looked especially closely at cardiovascular events; the only significant, between-treatment difference was in new hypertensive adverse events, which occurred significantly more often in the patients who received placebo for 3 years. ■

VITALS

Major Finding: Postmenopausal women with osteoporosis who received an annual injection of zoledronic acid for 6 years maintained their femoral neck bone mineral density significantly better than did those treated with the drug for 3 years followed by 3 years on placebo.

Data Source: Extension of the HORIZON Pivotal Fracture Trial, a randomized, multicenter extension trial with 1,233 women.

Disclosures: The HORIZON Pivotal Fracture Trial was funded by Novartis, which markets zoledronic acid (Aclasta). Dr. Black said that he has served as a consultant and done teaching for Amgen and Nycomed, and that he has received research contracts from Amgen, Merck, Novartis, and Roche/Genentech.

There's more for you at clinicalendocrinologynews.com:

Daily medical news, videos, and our blog and podcast . . . plus full-text archives with Medline-enhanced search capability



Patients with Renal Impairment: The dose of ONGLYZA is 2.5 mg once daily for patients with moderate or severe renal impairment, or with end-stage renal disease requiring hemodialysis (creatinine clearance [CrCl] \leq 50 mL/min). ONGLYZA should be administered following hemodialysis. ONGLYZA has not been studied in patients undergoing peritoneal dialysis. Assessment of renal function is recommended prior to initiation of ONGLYZA and periodically thereafter.

Pregnant and Nursing Women: There are no adequate and well-controlled studies in pregnant women. ONGLYZA, like other antidiabetic medications, should be used during pregnancy only if clearly needed. It is not known whether saxagliptin is secreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when ONGLYZA is administered to a nursing woman.

Pediatric Patients: Safety and effectiveness of ONGLYZA in pediatric patients have not been established.

For more information about Onglyza, visit www.onglyza.com/three.

Please read the adjacent Brief Summary of the Product Information.

*Pioglitazone or rosiglitazone

†Based on Tier 2 coverage and the Onglyza Value Card Program.

See Onglyza Value Card Program details at www.onglyza.com/hcp/value-card.aspx.

Reference: 1. Fingertip Formulary® data as of April 9, 2010. Data on File, April 2010.



onglyza[™]
(saxagliptin) 5 mg tablets

Bristol-Myers Squibb

©2010 Bristol-Myers Squibb 422US10AB08411 05/10
Onglyza[™] is a trademark of Bristol-Myers Squibb

AstraZeneca

307520